MedElevator Войти в исследования
← Поиск публикаций

DOI 10.57264/cer-2023-0142

Медицинская библиотека · Journal of comparative effectiveness research · 2023

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting.

Russell-Smith Alexander, Murphy Louise, Nguyen Amy, Blauer-Peterson Cori, Terpenning Marilou, Cao Feng, Li Shiqiang, Bancroft Tim, Webb Noah, Dorman Stephanie, Shah Richa

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Aim: To compare all-cause and acute lymphoblastic leukemia (ALL)-related healthcare resource utilization (HCRU) and costs among patients receiving inotuzumab ozogamicin (InO) and blinatumomab (Blina) for ALL in the first relapsed/refractory (R/R) setting. Patients & methods: We studied retrospective claims for adult commercial and Medicare Advantage enrollees with ALL receiving InO (n = 29) or Blina (n = 23) from 1 January 2015 to 16 February 2021. Mean per-patient-per-month (PPPM) HCRU and total costs were described and multivariable-adjusted PPPM total all-cause and ALL-related predicted costs were calculated.

Results

Mean monthly ALL-related hospitalizations were the same for patients receiving InO and Blina (PPPM = 0.8 stays); however, the length of ALL-related hospital stay was almost twice as long among patients receiving Blina versus InO (ALL-related: InO = 7.6 days; Blina = 14.1 days; p = 0.346). In multivariable models, total ALL-related costs were 43% lower for InO compared with Blina (PPPM costs: InO = $93,767; Blina = $163,470; p = 0.021).

Conclusion

In the first R/R setting, patients who used InO had significantly lower all-cause and ALL-related costs compared with patients who used Blina, in part driven by hospitalization patterns.

Для цитирования: Russell-Smith Alexander, Murphy Louise, Nguyen Amy, Blauer-Peterson Cori, Terpenning Marilou, Cao Feng, Li Shiqiang, Bancroft Tim, Webb Noah, Dorman Stephanie, Shah Richa. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting.. Journal of comparative effectiveness research. 2023. DOI: 10.57264/cer-2023-0142.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.